Abstract
A new peptidic protease inhibitor (MpI) has been isolated from Maclura pomifera seeds, being the first trypsin and chymotrypsin inhibitor from a species belonging to the family Moraceae. MpI was purified by acetone precipitation, gel filtration and ion exchange chromatography, successively, with purification factors of 112 and 109 for the aforementioned enzymes, which are infrequent high values for inhibitors isolated from seeds. MpI showed a unique band in SDSTricine PAGE (Mr 11 kDa) and isoelectric focusing (pI = 5.2), inhibited the serine proteases trypsin and α-chymotrypsin (IC50 0.17 and 0.7 μg/ml, respectively), but not cathepsin B (cysteine protease), cathepsin D (aspartic protease) nor carboxypeptidase A (metallo protease). The N-terminal sequence was determined (AREPKFSTHCEEEESR) but no homology was detected with other peptide inhibitors isolated from seeds. Preliminary assays related to blood clotting reactions showed that the isolated inhibitor significatively increased the activated partial thromboplastin time (APTT), suggesting its potential use in the treatment of blood coagulation disorders.
Keywords: Maclura pomifera seeds, Peptide trypsin inhibitor, Peptide α-chymotrypsin inhibitor, Moraceae
Letters in Drug Design & Discovery
Title: A Novel Trypsin and α-Chymotrypsin Inhibitor from Maclura pomifera Seeds
Volume: 7 Issue: 4
Author(s): C. M. Lazza, S. A. Trejo, W. D. Obregon, L. G. Pistaccio, N. O. Caffini and L. M.I. Lopez
Affiliation:
Keywords: Maclura pomifera seeds, Peptide trypsin inhibitor, Peptide α-chymotrypsin inhibitor, Moraceae
Abstract: A new peptidic protease inhibitor (MpI) has been isolated from Maclura pomifera seeds, being the first trypsin and chymotrypsin inhibitor from a species belonging to the family Moraceae. MpI was purified by acetone precipitation, gel filtration and ion exchange chromatography, successively, with purification factors of 112 and 109 for the aforementioned enzymes, which are infrequent high values for inhibitors isolated from seeds. MpI showed a unique band in SDSTricine PAGE (Mr 11 kDa) and isoelectric focusing (pI = 5.2), inhibited the serine proteases trypsin and α-chymotrypsin (IC50 0.17 and 0.7 μg/ml, respectively), but not cathepsin B (cysteine protease), cathepsin D (aspartic protease) nor carboxypeptidase A (metallo protease). The N-terminal sequence was determined (AREPKFSTHCEEEESR) but no homology was detected with other peptide inhibitors isolated from seeds. Preliminary assays related to blood clotting reactions showed that the isolated inhibitor significatively increased the activated partial thromboplastin time (APTT), suggesting its potential use in the treatment of blood coagulation disorders.
Export Options
About this article
Cite this article as:
Lazza M. C., Trejo A. S., Obregon D. W., Pistaccio G. L., Caffini O. N. and Lopez M.I. L., A Novel Trypsin and α-Chymotrypsin Inhibitor from Maclura pomifera Seeds, Letters in Drug Design & Discovery 2010; 7(4) . https://dx.doi.org/10.2174/157018010790945832
DOI https://dx.doi.org/10.2174/157018010790945832 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials A Hybrid Evolutionary System for Automated Artificial Neural Networks Generation and Simplification in Biomedical Applications
Current Bioinformatics The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design Implications of Melatonin Therapy in Irritable Bowel Syndrome: A Systematic Review
Current Pharmaceutical Design CDC25 Inhibitors as Anticancer Agents Are Moving Forward
Anti-Cancer Agents in Medicinal Chemistry CRH Receptor Signalling: Potential Roles in Pathophysiology
Current Molecular Pharmacology Phagoptosis - Cell Death By Phagocytosis - Plays Central Roles in Physiology, Host Defense and Pathology
Current Molecular Medicine The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer
Current Molecular Medicine Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry Regulation of HIPK Proteins by MicroRNAs
MicroRNA Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery Polyphenolic Compounds: Interactions with the Gut and Implications for Human Health
Current Medicinal Chemistry Utilizing Cancer - Functional Gene Set - Compound Networks to Identify Putative Drugs for Breast Cancer
Combinatorial Chemistry & High Throughput Screening The Human Leukocyte Antigen Class III Haplotype Approach: New Insight in Alzheimer's Disease Inflammation Hypothesis
Current Alzheimer Research Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Transient Expression of Chicken Antimicrobial Peptides by Mouse Mammary Carcinoma Cells C127
Protein & Peptide Letters